selenium has been researched along with quinazolines in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brychzy, A; de Paulsen, N; Fournier, MC; Gnarra, JR; Klausner, RD; Lee, S; Pause, A | 1 |
| Schiller, JH | 1 |
| Furukawa, S; He, Y; Koketsu, M; Nishina, A; Sekiguchi, A | 1 |
| Encío, I; Font, M; Lamberto, I; Moreno, E; Palop, JA; Plano, D; Sanmartín, C | 1 |
| An, B; Chan, ASC; Hu, J; Huang, L; Li, X; Pan, T; Tang, JC; Zhang, S | 1 |
1 review(s) available for selenium and quinazolines
| Article | Year |
|---|---|
Adjuvant systemic therapies in early-stage non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoprevention; Chemotherapy, Adjuvant; Drug Resistance; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Metastasis; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy, Adjuvant; Selenium; Survival Analysis | 2003 |
1 trial(s) available for selenium and quinazolines
| Article | Year |
|---|---|
Adjuvant systemic therapies in early-stage non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoprevention; Chemotherapy, Adjuvant; Drug Resistance; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Metastasis; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy, Adjuvant; Selenium; Survival Analysis | 2003 |
4 other study(ies) available for selenium and quinazolines
| Article | Year |
|---|---|
Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis.
Topics: Adenocarcinoma, Clear Cell; Cell Division; Cell Hypoxia; Enzyme Inhibitors; ErbB Receptors; Gene Expression Regulation; Genes, Tumor Suppressor; Growth Substances; Humans; Insulin; Kidney Neoplasms; Ligases; Oligodeoxyribonucleotides, Antisense; Proteins; Quinazolines; Selenium; Transferrin; Transforming Growth Factor alpha; Tumor Cells, Cultured; Tumor Suppressor Proteins; Tyrphostins; Ubiquitin-Protein Ligases; von Hippel-Lindau Disease; Von Hippel-Lindau Tumor Suppressor Protein | 2001 |
Ebselen, a redox regulator containing a selenium atom, induces neurofilament M expression in cultured rat pheochromocytoma PC12 cells via activation of mitogen-activated protein kinase.
Topics: Animals; Antioxidants; Azoles; Butadienes; Carbazoles; Enzyme Activation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; GTP-Binding Protein alpha Subunits, Gi-Go; GTP-Binding Protein alpha Subunits, Gq-G11; Indole Alkaloids; Isoindoles; Mitogen-Activated Protein Kinases; Neurites; Neurofilament Proteins; Nitriles; Organoselenium Compounds; Oxidation-Reduction; PC12 Cells; Pertussis Toxin; Phosphorylation; Quinazolines; Rats; Receptor Protein-Tyrosine Kinases; Selenium; Tyrphostins | 2008 |
Sulfur and selenium derivatives of quinazoline and pyrido[2,3-d]pyrimidine: synthesis and study of their potential cytotoxic activity in vitro.
Topics: Absorption; Antineoplastic Agents; Cell Cycle; Cell Death; Cell Line, Tumor; Humans; Pyrimidines; Quinazolines; Selenium; Sulfur | 2012 |
The design, synthesis and evaluation of selenium-containing 4-anilinoquinazoline hybrids as anticancer agents and a study of their mechanism.
Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Chemistry Techniques, Synthetic; Drug Design; Drug Screening Assays, Antitumor; Humans; Membrane Potential, Mitochondrial; Microtubules; Mitosis; Protein Multimerization; Protein Structure, Quaternary; Quinazolines; Reactive Oxygen Species; Selenium; Tubulin | 2018 |